JP6966998B2 - 口腔、咽喉及び気道の障害の治療のための配合物 - Google Patents
口腔、咽喉及び気道の障害の治療のための配合物 Download PDFInfo
- Publication number
- JP6966998B2 JP6966998B2 JP2018516646A JP2018516646A JP6966998B2 JP 6966998 B2 JP6966998 B2 JP 6966998B2 JP 2018516646 A JP2018516646 A JP 2018516646A JP 2018516646 A JP2018516646 A JP 2018516646A JP 6966998 B2 JP6966998 B2 JP 6966998B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- composition
- officinale
- weight
- throat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
クルクマ・ロンガ抽出物:20mg〜100mg
ピューニカ・グラネイタム抽出物(40%エラグ酸誘導体含有):10mg〜60mg
ジンギベル・オフィキナレ抽出物(35%ギンゲロール含有):2mg〜20mg
クルクマ・ロンガ抽出物:50mg
ピューニカ・グラネイタム抽出物(40%エラグ酸誘導体含有):20mg
ジンギベル・オフィキナレ抽出物(35%ギンゲロール含有):10mg
これらの量は各々±15%の範囲で変動可能である。
クルクマ・ロンガアルコール抽出物(ウコン)又は他の種(other species):50mg
ピューニカ・グラネイタム抽出物40%エラグ酸誘導体:20mg
ジンギベル・オフィキナレ脂溶性抽出物35%ギンゲロール:8mg
キシリトール:430mg
ヒアルロン酸:200mg
グリチルリチン酸アンモニウム:10mg
シクラミン酸ナトリウム:40mg
ポリソルベート80:5mg
クルクマ・ロンガアルコール抽出物(ウコン)又は他の種(other species):50mg
ピューニカ・グラネイタム抽出物40%エラグ酸誘導体:20mg
ジンギベル・オフィキナレ脂溶性抽出物:10mg
アルギン酸ナトリウム塩:200mg
キシリトール:600mg
グリチルリチン酸アンモニウム:10mg
シクラミン酸ナトリウム:40mg
ポリソルベート80:5mg
本研究には多数の患者(1群当たり60人超)が参加した。被験体に任意のサプリメント又は治療についての情報を与え、サプリメントが何であるかを知らせた。生じ得るプラシーボ効果を慎重に説明し、検討した。データを観察期間後に、理想的には十分な証拠が収集された時点で分析した。群間差を認めるのに要する時間も評価標的とみなした。
1.「ヒリヒリした」咽喉痛
2.くしゃみ
3.鼻漏
4.鼻閉塞
5.倦怠感
6.咳
7.発熱
a−エピソードの出現の評価
b−兆候/症状の低減
c−疾患の日数の低減、他の対症療法の使用の低減
d−感冒関連潜在的合併症の制御
e−唾液及びリゾチーム含量の決定
Claims (11)
- 感冒、細菌感染又はウィルス感染によって引き起こされる、口腔、咽喉及び気道の障害の予防及び/又は治療における使用のためのクルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの植物部位の抽出物からなる活性物質の組成物であって、該抽出物が、乾燥抽出物ベースで、それぞれの重量比6(±2):2(±1):1(±0.5)で存在し、
クルクマ・ロンガの前記植物部位は根及び根茎から選択され、アルコール溶媒が抽出物の調製に用いられ、
ピューニカ・グラネイタムの前記植物部位は果実全体であり、エタノール/水又はアセトンの混合物が抽出物の調製に用いられ、
ジンギベル・オフィキナレの前記植物部位は根茎であり、超臨界条件でのn−ヘキサン又はCO2が抽出物の調製に用いられる、感冒、細菌感染又はウィルス感染によって引き起こされる、口腔、咽喉及び気道の障害の予防及び/又は治療における使用のための組成物。 - 感冒、細菌感染又はウィルス感染によって引き起こされる、口腔、咽喉及び気道の障害の予防及び/又は治療における使用のためのクルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの植物部位の抽出物を含む活性物質の組合せを含む組成物であって、該抽出物が、乾燥抽出物ベースで、それぞれの重量比6(±2):2(±1):1(±0.5)で存在し、
クルクマ・ロンガの前記植物部位は根及び根茎から選択され、アルコール溶媒が抽出物の調製に用いられ、
ピューニカ・グラネイタムの前記植物部位は果実全体であり、エタノール/水又はアセトンの混合物が抽出物の調製に用いられ、
ジンギベル・オフィキナレの前記植物部位は根茎であり、超臨界条件でのn−ヘキサン又はCO2が抽出物の調製に用いられ、
前記抽出物が全体として全投与活性物質の50重量%超を占め、及び/又は、
前記抽出物以外の各々の考え得る活性物質が、前記クルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物のうち最低のものよりも少なくとも50重量%低い量で存在する、感冒、細菌感染又はウィルス感染によって引き起こされる、口腔、咽喉及び気道の障害の予防及び/又は治療における使用のための組成物。 - 前記クルクマ・ロンガ、ピューニカ・グラネイタム及びジンギベル・オフィキナレの抽出物が全体として全投与活性物質の90重量%超を占める、請求項2に記載の使用のための組成物。
- 前記クルクマ・ロンガの抽出物がクルクミノイドを20重量%〜30重量%の量で含有し、前記ピューニカ・グラネイタムの抽出物がポリフェノールを60重量%〜95重量%の量で含有し、前記ジンギベル・オフィキナレの抽出物がギンゲロール及びショウガオールを合計して20重量%〜50重量%の量で含有する、請求項1〜3のいずれか一項に記載の使用のための組成物。
- 20mg〜100mgのクルクマ・ロンガ抽出物と、10mg〜50mgのピューニカ・グラネイタム抽出物と、2mg〜20mgのジンギベル・オフィキナレ抽出物とを含む投与単位用量として配合される、請求項1〜4のいずれか一項に記載の使用のための組成物。
- 医薬賦形剤が配合される、請求項1〜5のいずれか一項に記載の使用のための組成物。
- 口腔投与、経口投与又は吸入投与に好適な形態である、請求項1〜6のいずれか一項に記載の使用のための組成物。
- 前記障害が細菌活性と関連する、請求項1〜7のいずれか一項に記載の使用のための組成物。
- 前記障害が普通感冒又はインフルエンザの結果として生じる、請求項1〜8のいずれか一項に記載の使用のための組成物。
- 前記障害が上咽頭炎、鼻咽喉炎、咽喉痛、咳、鼻水、耳及び/又は咽喉の合併症、呼吸困難、気管支炎、肺炎、くしゃみ、鼻漏、鼻閉塞、並びに関連病態の1つ以上である、請求項1〜9のいずれか一項に記載の使用のための組成物。
- 前記組成物と唾液との接触により生体異物の溶解を増進するために更に使用される、請求項1〜10のいずれか一項に記載の使用のための組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15171354.2A EP3103464A1 (en) | 2015-06-10 | 2015-06-10 | Formulations for the treatment of disorders of the mouth, throat and respiratory tract |
EP15171354.2 | 2015-06-10 | ||
PCT/IB2016/000795 WO2016198943A1 (en) | 2015-06-10 | 2016-06-10 | Formulations for the treatment of disorders of the mouth, throat and respiratory tract |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018519361A JP2018519361A (ja) | 2018-07-19 |
JP6966998B2 true JP6966998B2 (ja) | 2021-11-17 |
Family
ID=53396312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018516646A Active JP6966998B2 (ja) | 2015-06-10 | 2016-06-10 | 口腔、咽喉及び気道の障害の治療のための配合物 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10758587B2 (ja) |
EP (2) | EP3103464A1 (ja) |
JP (1) | JP6966998B2 (ja) |
KR (1) | KR20180030970A (ja) |
CN (1) | CN108040468B (ja) |
AU (1) | AU2016276145B2 (ja) |
BR (1) | BR112017026417B1 (ja) |
ES (1) | ES2730088T3 (ja) |
HU (1) | HUE044731T2 (ja) |
MX (1) | MX2017016028A (ja) |
PL (1) | PL3307293T3 (ja) |
PT (1) | PT3307293T (ja) |
TR (1) | TR201908938T4 (ja) |
WO (1) | WO2016198943A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3103465A1 (en) * | 2015-06-10 | 2016-12-14 | Raman Mehta | Formulations for the treatment of mucosal lesions |
KR102224051B1 (ko) * | 2019-04-04 | 2021-03-09 | 한국 한의학 연구원 | 건강 추출물을 유효성분으로 포함하는 중화항체 생성율 증진용 조성물 |
IT202000018949A1 (it) | 2020-08-03 | 2022-02-03 | Arterra Bioscience S P A | Estratto derivato da bucce di punica granatum per la prevenzione e il trattamento di infezioni virali |
IT202000026566A1 (it) * | 2020-11-06 | 2022-05-06 | Herbal E Antioxidant Derivatives Srl Ed In Forma Abbreviata H&Ad Srl | Combinazioni di antivirali e antimicrobici naturali, loro uso e formulazioni che le contengono |
WO2023037299A1 (en) * | 2021-09-09 | 2023-03-16 | Integria Healthcare (Australia) Pty Limited | Anti-inflammatory compositions comprising ginger and turmeric |
TR2022000292A2 (tr) | 2022-01-11 | 2022-02-21 | Tuerkiye Bilimsel Veteknolojik Arastirma Kurumu | SARS-CoV-2 Virüsüne Karşı Koruyucu Pastil/Çiğneme Tableti Üretimi |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596313B2 (en) | 2001-08-06 | 2003-07-22 | The Quigley Corporation | Nutritional supplement and methods of using it |
JP2007153888A (ja) * | 2005-11-14 | 2007-06-21 | Kanebo Foods Ltd | 体内浄化用組成物、それを用いた食品、入浴剤、化粧料、製剤及び有害金属***促進剤 |
US20090175971A1 (en) | 2008-01-08 | 2009-07-09 | Mark Dreher | Method of using composition comprising pomegranate extracts against the common cold |
DE202009002126U1 (de) * | 2009-02-13 | 2009-04-16 | Orthomol Pharmazeutische Vertriebs Gmbh | Spurenelement enthaltende Zusammensetzung |
KR101077920B1 (ko) | 2009-07-08 | 2011-10-31 | 한국생명공학연구원 | 울금 추출물을 포함하는 인플루엔자 바이러스 감염의 예방 및 치료용 조성물 및 뉴라미니데이즈 활성의 억제용 조성물 |
BR112012013345A2 (pt) * | 2009-12-04 | 2016-03-01 | Colgate Palmolive Co | composições orais contendo uma combinação de extratos naturais e métodos relacionados |
IT1402018B1 (it) | 2010-10-11 | 2013-08-28 | Indena Spa | Formulazioni per il trattamento delle affezioni delle prime vie respiratorie. |
JP2013001666A (ja) * | 2011-06-14 | 2013-01-07 | Yasuharu Omura | 栄養剤組成物 |
CN102670588B (zh) | 2012-05-04 | 2013-11-20 | 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 | 鞣花酸用于制备抗病毒药物的应用 |
CN103638502B (zh) | 2013-12-12 | 2015-07-01 | 苏振华 | 一种治疗白塞病的药物及其制备方法 |
CN104524508A (zh) | 2014-12-24 | 2015-04-22 | 赵红 | 一种治疗消化性溃疡的中药及其制备方法 |
-
2015
- 2015-06-10 EP EP15171354.2A patent/EP3103464A1/en not_active Withdrawn
-
2016
- 2016-06-10 WO PCT/IB2016/000795 patent/WO2016198943A1/en active Application Filing
- 2016-06-10 KR KR1020177037808A patent/KR20180030970A/ko not_active Application Discontinuation
- 2016-06-10 MX MX2017016028A patent/MX2017016028A/es unknown
- 2016-06-10 TR TR2019/08938T patent/TR201908938T4/tr unknown
- 2016-06-10 EP EP16732747.7A patent/EP3307293B1/en active Active
- 2016-06-10 HU HUE16732747 patent/HUE044731T2/hu unknown
- 2016-06-10 PT PT16732747T patent/PT3307293T/pt unknown
- 2016-06-10 BR BR112017026417-0A patent/BR112017026417B1/pt active IP Right Grant
- 2016-06-10 JP JP2018516646A patent/JP6966998B2/ja active Active
- 2016-06-10 CN CN201680032969.4A patent/CN108040468B/zh active Active
- 2016-06-10 US US15/735,361 patent/US10758587B2/en active Active
- 2016-06-10 ES ES16732747T patent/ES2730088T3/es active Active
- 2016-06-10 PL PL16732747T patent/PL3307293T3/pl unknown
- 2016-06-10 AU AU2016276145A patent/AU2016276145B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3103464A1 (en) | 2016-12-14 |
CN108040468A (zh) | 2018-05-15 |
KR20180030970A (ko) | 2018-03-27 |
ES2730088T3 (es) | 2019-11-08 |
AU2016276145A1 (en) | 2017-12-21 |
WO2016198943A1 (en) | 2016-12-15 |
CN108040468B (zh) | 2021-08-20 |
AU2016276145B2 (en) | 2022-05-26 |
US10758587B2 (en) | 2020-09-01 |
EP3307293A1 (en) | 2018-04-18 |
JP2018519361A (ja) | 2018-07-19 |
MX2017016028A (es) | 2018-04-13 |
BR112017026417B1 (pt) | 2021-04-27 |
TR201908938T4 (tr) | 2019-07-22 |
PT3307293T (pt) | 2019-06-12 |
EP3307293B1 (en) | 2019-03-20 |
US20180169175A1 (en) | 2018-06-21 |
PL3307293T3 (pl) | 2019-11-29 |
HUE044731T2 (hu) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6966998B2 (ja) | 口腔、咽喉及び気道の障害の治療のための配合物 | |
KR100934955B1 (ko) | 약학적 조성물 및 그 이용 방법 | |
Siveen et al. | Augmentation of humoral and cell mediated immune responses by Thujone | |
Prajapati et al. | An exhaustive comprehension of the role of herbal medicines in Pre-and Post-COVID manifestations | |
Brendler et al. | Devil’s Claw (Harpagophytum procumbens DC) an evidence-based systematic review by the natural standard research collaboration | |
US20170020946A1 (en) | Analgesic compositions and methods of use | |
JP6830482B2 (ja) | 粘膜病変の治療のための配合物 | |
US20210308071A1 (en) | Treatment method to abort and or reduce the severity of upper respiratory viral illness as well as to prevent upper respiratory viral illness in humans | |
JP2006206461A (ja) | アレルギー疾患の予防・治療用組成物 | |
JP5950493B2 (ja) | 疲労回復剤 | |
Kumari et al. | Modulating effects of Curcuma longa (turmeric) and Piper nigrum (black pepper) extracts against adriamycin induced genotoxicity in Swiss albino mice | |
Upadhyay et al. | Aromatic Plants, Essential oils, Carminatives, Tea Plants and Expectorant Herbs for the Management of COVID-19 | |
Kadawla et al. | Investigating the Synergistic In-vitro Anti-inflammatory Potentials of Standardized Fruit Extract of Eugenia jambolana and Standardized Fruit Extract Piper nigrum Combinations | |
WO2022123605A1 (en) | Herbal composition for covid 19 treatment | |
AU2016100033A4 (en) | Biopharmaceutical with antiviral activity. | |
Ahmed et al. | EVALUATING CLINICAL EFFICACY OF TULSI AEROSOL IN THE MANAGEMENT OF UPPER RESPIRATORY TRACT INFECTION WSR TO PRATISHYAY-A PILOT STUDY | |
Jubayer et al. | Therapeutic Potential of Selective Medicinal Plants and Their Phytoconstituents Focusing the Prevention and Cure of COVID-19 | |
JP2023527409A (ja) | Covid-19および関連する疾患の管理のための組成物 | |
AU2020220942A1 (en) | Synergistic composition with anti-proliferative activity | |
EP1112745A1 (en) | Homeopathic composition | |
IT202000026566A1 (it) | Combinazioni di antivirali e antimicrobici naturali, loro uso e formulazioni che le contengono | |
EP2552466A1 (de) | Zusammensetzung enthaltend bestandteile aus sonnenhut, holunder und kamille zur behandlung von erkältungskrankheiten | |
WO2012129957A1 (zh) | 几种药物配方 | |
JP2009508806A (ja) | コリンエステラーゼ賦活剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20180115 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20180518 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200225 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200601 |
|
A603 | Late request for extension of time limit during examination |
Free format text: JAPANESE INTERMEDIATE CODE: A603 Effective date: 20200601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200722 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210319 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211005 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211019 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211022 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6966998 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |